Agios Pharmaceuticals (AGIO) Projected to Post Earnings on Wednesday

Agios Pharmaceuticals (NASDAQ:AGIO) is anticipated to release its Q1 2026 results before the market opens on Wednesday, April 29th. Analysts expect the company to announce earnings of ($1.82) per share and revenue of $13.9110 million for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 8:00 AM ET.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ:AGIO traded up $0.39 during midday trading on Tuesday, hitting $24.82. 200,969 shares of the company’s stock traded hands, compared to its average volume of 997,580. The firm’s fifty day moving average price is $29.93 and its two-hundred day moving average price is $31.19. Agios Pharmaceuticals has a twelve month low of $22.24 and a twelve month high of $46.00. The company has a market cap of $1.45 billion, a PE ratio of -3.49 and a beta of 0.79.

Insider Buying and Selling

In other news, insider Tsveta Milanova sold 3,262 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total transaction of $113,224.02. Following the completion of the sale, the insider directly owned 46,829 shares in the company, valued at $1,625,434.59. This trade represents a 6.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sarah Gheuens sold 2,940 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $102,047.40. Following the sale, the insider directly owned 80,277 shares in the company, valued at approximately $2,786,414.67. The trade was a 3.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 15,582 shares of company stock worth $520,405 over the last quarter. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of AGIO. AQR Capital Management LLC lifted its stake in shares of Agios Pharmaceuticals by 66.8% in the first quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company’s stock worth $1,498,000 after acquiring an additional 20,625 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Agios Pharmaceuticals by 7.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company’s stock worth $1,274,000 after acquiring an additional 2,920 shares in the last quarter. NewEdge Advisors LLC acquired a new position in shares of Agios Pharmaceuticals in the first quarter worth about $40,000. Goldman Sachs Group Inc. lifted its stake in shares of Agios Pharmaceuticals by 16.1% in the first quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company’s stock worth $19,299,000 after acquiring an additional 91,482 shares in the last quarter. Finally, Woodline Partners LP acquired a new position in shares of Agios Pharmaceuticals in the first quarter worth about $597,000.

Wall Street Analyst Weigh In

A number of research analysts have commented on AGIO shares. Wall Street Zen upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. Bank of America decreased their target price on Agios Pharmaceuticals from $44.00 to $41.00 and set a “buy” rating for the company in a research report on Tuesday, April 21st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Friday, March 27th. The Goldman Sachs Group upped their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 1st. Finally, HC Wainwright lowered their price objective on shares of Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, April 20th. Six analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $41.78.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.